Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: Plain language summary Review
| Authors: | Dy, G. K.; Govindan, R.; Velcheti, V.; Falchook, G. S.; Italiano, A.; Wolf, J.; Sacher, A. G.; Takahashi, T.; Ramalingam, S. S.; Dooms, C.; Kim, D. W.; Addeo, A.; Desai, J.; Schuler, M.; Tomasini, P.; Hong, D. S.; Lito, P.; Tran, Q.; Jones, S.; Anderson, A.; Hindoyan, A.; Snyder, W.; Skoulidis, F.; Li, B. T. |
| Review Title: | Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: Plain language summary |
| Abstract: | What is this summary about? This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer. CodeBreaK 100 specifically looked at patients with a particular change(mutation) in the KRAS gene resulting in the mutated protein called KRAS G12C. The KRAS G12C mutation can lead to development and growth of lung cancer. Patients received a treatment called sotorasib, which has accelerated approval or full approval in over 50 countries for patients with non-small-cell lung cancer with the KRAS G12C mutation. The CodeBreaK 100 study looked at whether sotorasib is a safe and effective treatment for advanced non-small-cell lung cancer. Sotorasib is designed to specifically target and lock the mutated KRAS protein in the inactive state to treat non-small-cell lung cancer. What were the results? In total, 174 adults were treated with sotorasib. Treatment-related side effects were seen in 70% of patients and were severe in 21% of patients. The most common side effects included diarrhea, increased liver enzymes, nausea and tiredness. 70 (41%) patients responded to sotorasib and 144 (84%) patients had tumors that either remained stable or shrunk in size. 29 (41%) patients who responded to sotorasib responded for over 12 months. After 2 years, 9 patients with a response remained on sotorasib; there were no notable increases in tumor size or development of new tumors over this time. There were 5patients who received sotorasib for more than 2 years and continued to respond. Long-term benefit was seen for some patients. Patients also benefitted from treatment when the tumor expressed different amounts of a protein called PD-L1.In total, 33% of patients were still alive after 2 years. What do the results mean? Results show the long-term benefit of sotorasib therapy for people with advanced KRAS G12C-mutated non-small-cell lung cancer. Clinical Trial Registration: NCT03600883 (CodeBreaK 100) (ClinicalTrials.gov) </sec. © 2023 The Authors. |
| Keywords: | adult; genetics; mutation; pyridines; metastasis; carcinoma, non-small-cell lung; lung neoplasms; pyrimidines; lung tumor; lung; piperazines; language; piperazine derivative; pyrimidine derivative; protein p21; proto-oncogene proteins p21(ras); clinical trials; kras protein, human; pyridine derivative; non small cell lung cancer; humans; human; sotorasib |
| Journal Title: | Future Oncology |
| Volume: | 20 |
| Issue: | 3 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2024-01-01 |
| Start Page: | 113 |
| End Page: | 120 |
| Language: | English |
| DOI: | 10.2217/fon-2023-0560 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work